Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3823932 | 0.89 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL12850165 | 0.88 | LMNA (0.45) | PTGS2PTGS1LMNANPC1RAB9A | |
| SCHEMBL12799636 | 0.82 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL12799650 | 0.79 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL3859758 | 0.78 | PTGS2 (0.62) | PTGS2PTGS1 | |
| SCHEMBL12799620 | 0.78 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL12799638 | 0.76 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL12799649 | 0.76 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL12799613 | 0.76 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL12799642 | 0.75 | PTGS2 (0.53) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906551-B2 | 3-substituted-1,5-diarly-2-alkyl-pyrroles highly selective and orally effective COX-2 inhibitors | ROTTAPHARM S.P.A. (IT) | 2011-03-15 | — | — | US | disclosed |
| US-20090264500-A1 | 3-SUBSTITUTED-1,5-DIARLY-2-ALKYL-PYRROLES HIGHLY SELECTIVE AND ORALLY EFFECTIVE COX-2 INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264500-A1 | 3-SUBSTITUTED-1,5-DIARLY-2-ALKYL-PYRROLES HIGHLY SELECTIVE AND ORALLY EFFECTIVE COX-2 INHIBITORS | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885LMNA 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.